p16 INK4a expression in basal-like breast carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 6, 2010, Pages 600-607

  Bohn, Olga L ^a,b   Fuertes Camilo, Mariana ^b   Navarro, Leticia ^b   Saldivar, Jesus ^b   Sanchez Sosa, Sergio ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Grupo Christus Muguerza   (Mexico)

Author keywords

Basal cancer; Breast cancer; Estrogen receptor; HER2; Immunohistochemistry; p16 INK4a; Progesterone receptor

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BASAL CELL CARCINOMA; BIOSYNTHESIS; BREAST TUMOR; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; TISSUE MICROARRAY;

BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, BASAL CELL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS;

EID: 77956022281     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al. Molecular portraits of human breast tumours. Nature 2000; 406 (6797):747-752.
2. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26(8):1275-1281.
3. Reis-Filho JS, Tutt AN: Triple negative tumours: a critical review. Histopathology 2008; 52(1):108-118.
4. Bryan BB, Schnitt SJ, Collins LC: Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 2006; 19(5):617-621.
5. Pintens S, Neven P, Drijkoningen M, Van Belle V, Moerman P, Christiaens MR, Smeets A, Wildiers H, Vanden Bempt I: Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1. J Clin Pathol 2009; 62 (7):624-628.
6. Beasley MB, Lantuejoul S, Abbondanzo S, Chu WS, Hasleton PS, Travis WD, Brambilla E: The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 2003; 34(2):136-142.
7. Brambilla E, Moro D, Gazzeri S, Brambilla C: Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 1999; 188 (4):351-360.
8. Brambilla E, Gazzeri S, Moro D, Lantuejoul S, Veyrenc S, Brambilla C: Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res 1999; 5(2):243-250.
9. Yin M, Bastacky S, Parwani AV, McHale T, Dhir R: p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ. Hum Pathol 2008; 39(4):527-535.
10. Santos M, Montagut C, Mellado B, Garcia A, Ramon y Cajal S, Cardesa A, Puig-Tintore LM, Ordi J: Immunohistochemical staining for p16 and p53 in premalignant and malignant epithelial lesions of the vulva. Int J Gynecol Pathol 2004; 23(3):206-214.
11. Ortega S, Malumbres M, Barbacid M: Cyclin Ddependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002; 1602(1):73-87.
12. Sherr CJ: Cancer cell cycles. Science 1996; 274 (5293):1672-1677.
13. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98(19):10869-10874.
14. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol 2006; 24 (23):3726-3734.
15. Lin Y, Lin S, Watson M, Trinkaus KM, Kuo S, Naughton MJ, Weilbaecher K, Fleming TP, Aft RL: A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 2009.
16. Rakha E, Reis-Filho JS: Basal-like breast carcinoma: from expression profiling to routine practice. Arch Pathol Lab Med 2009; 133(6):860-868.
17. Fadare O, Tavassoli FA: The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol 2007; 14(5):358-373.
18. Da Silva L, Clarke C, Lakhani SR: Demystifying basal-like breast carcinomas. J Clin Pathol 2007; 60(12):1328-1332.
19. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10(16):5367-5374.
20. Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, Hanby A: Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006; 49(1):22-34.
21. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR et al: Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002; 161(6):1991-1996.
22. Herschkowitz JI, He X, Fan C, Perou CM: The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 2008; 10(5):R75.
23. Malzahn K, Mitze M, Thoenes M, Moll R: Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 1998; 433(2):119-129.
24. Hui R, Macmillan RD, Kenny FS, Musgrove EA, Blamey RW, Nicholson RI, Robertson JF, Sutherland RL: INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res 2000; 6(7):2777-2787.
25. Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Loning T: Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 2001; 67(1):61-70.
26. Subhawong AP, Subhawong T, Nassar H, Kouprina N, Begum S, Vang R, Westra WH, Argani P: Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol 2009; 33(2):163-175.